サンプル依頼リスト カート
  • English
  • Korean
表紙：腫瘍内がん治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374881

腫瘍内がん治療の世界市場-2023年～2030年

Global Intratumoral Cancer Therapies Market - 2023-2030

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
腫瘍内がん治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

腫瘍内免疫療法は、腫瘍をそれ自身に対するワクチンとして標的とする治療法です。腫瘍内免疫療法は、腫瘍に直接注射することで、局所的な腫瘍免疫障害を直接標的とする有利な方法です。

この方法は、腫瘍に直接取り込まれることを意図して、腫瘍に解剖学的に近接しているあらゆる腫瘍を攻撃するために活用することもできます。腫瘍内治療には、サイトカイン、病原体関連分子パターン（PAMPs）、オンコライトウイルス、がん遺伝子治療、モノクローナル抗体、低分子化合物などの種類があります。

市場力学：市場促進要因と市場抑制要因

市場の発展の拡大

世界の腫瘍内がん治療市場における市場の発展は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、2023年1月、英国を拠点とする科学主導型のバイオ医薬品企業であるアストラゼネカは、ネオジーン・セラピューティクス社を1億2,000万米ドルで買収し、この買収によってアストラゼネカはがん治療のさらなるルートを切り開くと期待されています。

さらに2022年には、リジェネロンが臨床段階のバイオ医薬品企業であるチェックメイト・ファーマシューティカルと、複数の腫瘍型に使用される可能性のある同社の治験用免疫活性剤の買収を完了しました。さらに、認知度の向上、調査・研究活動の活発化なども、予測期間中の世界市場の成長に寄与すると予想されます。

腫瘍内がん治療に伴う副作用

しかし、がん治療によって引き起こされる一般的な副作用や、稀な重篤な副作用の多さが、予測期間中の世界市場の成長を妨げると予想されます。さらに、承認された治療法がないこと、高コストであること、専門家の数が不足していることなども、世界市場の成長を妨げる要因の1つです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 市場の発展の拡大
    • 抑制要因
      • 副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • パイプライン分析
  • 疫学分析
  • SWOT分析
  • DMIの見解

第6章 COVID-19分析

第7章 技術別

  • モノクローナル抗体
  • ワクチン
  • チェックポイント阻害剤
  • 細胞治療薬
  • 免疫系モジュレーター
  • 細胞移植
  • サイトカイン

第8章 がんの種類別

  • 肺がん
  • 乳がん
  • 悪性黒色腫
  • 前立腺がん
  • 頭頸部がん
  • その他の用途

第9章 エンドユーザー別

  • 病院
  • がん研究センター
  • クリニック

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Hoffmann-La Roche
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Pfizer
  • Bristol-Myers Squibb, Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi
  • Daiichi Sankyo
  • AstraZeneca, Inc.
  • Immunocore, Ltd
  • Biogen Inc.
  • Merck and Co. Inc.

第13章 付録

目次
Product Code: PH7217

Overview

Intratumoral immunotherapy is a probable therapeutic approach that targets the tumor using it as a vaccine against itself. It is an advantageous method that encloses direct injection into the tumors thereby targeting the regional tumor immunity hindrances directly.

It can even be leveraged to attack any tumor that fibs in proximate anatomical closeness to a tumor with the intent of immediate uptake by tumors. There are distinct types of intratumoral therapies including cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.

Market Dynamics: Drivers & Restraints

Increasing Market Developments

The increasing market developments in the global Intratumoral Cancer Therapies market are expected to boost the global market growth during the forecast period. For instance, in January 2023, AstraZeneca, a UK-based, science-driven biopharmaceutical corporation completed the acquisition of Neogene Therapeutics Inc., for $120 million and this acquisition is expected to unlock further routes for AstraZeneca for the treatment of cancer.

Moreover, in 2022, Regeneron completed the acquisition of Checkmate Pharmaceutical, a clinical-stage biopharmaceutical corporation, and its investigational immune activator for probable usage in multiple tumor types. Furthermore, growing awareness, cases and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Side Effects Associated with these Intratumoral Cancer Therapies

However, the large number of common and uncommon severe side effects cuased by cancer therapy are expected to hamper the global market growth during the forecast period. Furthermore, the lack of approved treatments available, high cost and deficient number of professionals are among the additional factors hampering the global market growth.

Segment Analysis

The global intratumoral cancer therapies market is segmented based on technology, cancer type, end user and region.

Lung Cancer Type is Expected to Dominate Market

Owing to the increase in new product approvals for lung cancer boosting the segment growth, dominating the global market in the forecast period. For instance, in October 2021, the U.S. FDA authorized Tecentriq (atezolizumab) to treat stage II and stage III Non-small cell lung cancer (NSCLC). Moreover, in April 2022, the U.S. FDA authorized Opdivo (nivolumab) for the treatment of NSCLC in adult patients. Furthermore, the growing cases of Lung cancer along with the increasing research activities are also expected to contribute to the dominance of the segment on the global market in the forecast period.

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to dominate the global market during the forecast period due to increasing government investments, growing cancer cases, and increasing product authorizations among others. For instance, in 2023, the US government announced a budget of USD 7.8 billion to the National Cancer Institute (NCI) for cancer research.

The government and private organizations' investment to expand the research and development of cancer therapies in the region is driving the growth of the North America Intratumoral Cancer Therapy Market.

According to the American Cancer Society, around 1.9 million cases of cancer were diagnosed in the US in 2022. Additionally, Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. Furthermore, the presence of various biotechnology and medical device firms in this region is likely to maintain their lead during the forecast period due to increased spending on research and development initiatives and widespread use of technology in the region.

COVID-19 Impact Analysis

Since some individuals with cancer are at raised threat of severe illness if they get COVID-19, owing to their immune systems have been strained by the cancer and/or its therapies. Individuals who were treated for cancer in the history (particularly if it was years ago) are better potential to have normal immune function. Thus, impacting the therapy demand during the forecast period.

Market Segmentation

By Technology

  • Monoclonal Antibodies
  • Vaccines
  • Checkpoint Inhibitors
  • Cell Therapies
  • Immunes System Modulator
  • Adoptive Cell Transfer
  • Cytokines

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Malenoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Other

By End User

  • Hospitals
  • Cancer Research Centres
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2022, Merck formed a USD290 million agreement with Orion to design a novel prostate cancer medicine.
  • In July 2022, Philogen reported the enrolment of 214 patients for clinical trial 3 of its latest Intratumoral drug Nidlegy for the treatment of locally advanced melanoma cancer.
  • In October 2022, Merck collaborated with Moderma to develop and commercialize personalized intratumoral cancer therapy for melanoma cancer.

Competitive Landscape

The major global players in the market include: Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Immunocore, Ltd, Merck and Co. Inc. and Biogen Inc. among others.

Why Purchase the Report?

  • To visualize the global intratumoral cancer therapies market segmentation based on technology, cancer type, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of intratumoral cancer therapies market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global intratumoral cancer therapies market report would provide approximately 61 tables, 59 figures and 194 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Technology
  • 3.2. Snippet by Cancer Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Monoclonal Antibodies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Vaccines
  • 7.4. Checkpoint Inhibitors
  • 7.5. Cell Therapies
  • 7.6. Immunes System Modulator
  • 7.7. Adoptive Cell Transfer
  • 7.8. Cytokines

8. By Cancer Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.1.2. Market Attractiveness Index, By Cancer Type
  • 8.2. Lung Cancer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Breast Cancer
  • 8.4. Malenoma
  • 8.5. Prostate Cancer
  • 8.6. Head and Neck Cancer
  • 8.7. Other Applications

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cancer Research Centres
  • 9.4. Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Hoffmann-La Roche*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer
  • 12.3. Bristol-Myers Squibb, Inc.
  • 12.4. Boehringer Ingelheim GmbH
  • 12.5. Sanofi
  • 12.6. Daiichi Sankyo
  • 12.7. AstraZeneca, Inc.
  • 12.8. Immunocore, Ltd
  • 12.9. Biogen Inc.
  • 12.10. Merck and Co. Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us